Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Rahma, OE"'
Publikováno v:
Journal of Hepatocellular Carcinoma, Vol Volume 7, Pp 11-17 (2020)
Prabhsimranjot Singh,1,2 Sudhamshi Toom,3 Akshay Avula,4 Vivek Kumar,2 Osama E Rahma1,2 1Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; 2Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; 3Hematology and Oncolo
Externí odkaz:
https://doaj.org/article/394124509a88418ebf4dde9072fb0e0b
Autor:
Duffy, AG, Ulahannan, SV, Cao, L, Rahma, OE, Makarova-Rusher, OV, Kleiner, DE, Fioravanti, S, Walker, M, Carey, S, Yu, Y, Venkatesan, AM, Turkbey, B, Choyke, P, Trepel, J, Bollen, KC, Steinberg, SM, Figg, WD, Greten, TF
Publikováno v:
United European Gastroenterology Journal; October 2015, Vol. 3 Issue: 5 p453-461, 9p
Autor:
Huffman BM; Dana-Farber Cancer Institute, Boston, MA, United States., Rahma OE; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Tyan K; Harvard University, Boston, United States., Li YY; Dana-Farber Cancer Institute, Boston, MA, United States., Giobbie-Hurder A; Dana-Farber Cancer Institute, Boston, MA, United States., Schlechter BL; Dana-Farber/Brigham and Women's Cancer Center / / Harvard Medical School, Boston, MA, United States., Bockorny B; Beth Israel Deaconess Medical Center, Boston, MA, United States., Manos MP; Dana-Farber Cancer Institute, Boston, MA, United States., Cherniack AD; Broad Institute of Harvard and MIT, Cambridge, MA, United States., Baginska J; Dana-Farber Cancer Institute, Boston, MA, United States., Mariño-Enríquez A; Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States., Kao KZ; Dana-Farber Cancer Institute, Boston, MA, United States., Maloney AK; Dana-Farber Cancer Institute, Boston, MA, United States., Ferro A; Dana-Farber Cancer Institute, United States., Kelland S; Dana-Farber Cancer Institute, Boston, MA, United States., Ng K; Dana-Farber Cancer Institute, Boston, MA, United States., Singh H; Dana-Farber Cancer Institute, Boston, MA, United States., Welsh EL; Dana-Farber Cancer Institute, Boston, United States., Pfaff KL; Dana-Farber Cancer Institute, Boston, MA, United States., Giannakis M; Dana-Farber Cancer Institute, Boston, MA, United States., Rodig SJ; Dana-Farber Cancer Institute, Boston, MA, United States., Hodi FS; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Cleary JM; Dana-Farber Cancer Institute, Boston, MA, United States.
Publikováno v:
Cancer immunology research [Cancer Immunol Res] 2024 Sep 30. Date of Electronic Publication: 2024 Sep 30.
Autor:
Oberstein PE; Department of Medicine, NYU Langone Health, New York, New York.; Perlmutter Cancer Center, NYU Langone Health, New York, New York., Dias Costa A; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Kawaler EA; Perlmutter Cancer Center, NYU Langone Health, New York, New York.; Department of Surgery, NYU Langone Health, New York, New York., Cardot-Ruffino V; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Immunology, Harvard Medical School, Boston, Massachusetts., Rahma OE; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Beri N; Department of Medicine, NYU Langone Health, New York, New York.; Perlmutter Cancer Center, NYU Langone Health, New York, New York., Singh H; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Abrams TA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Biller LH; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Cleary JM; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Enzinger P; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Huffman BM; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., McCleary NJ; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Perez KJ; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Rubinson DA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Schlechter BL; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Surana R; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Yurgelun MB; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Wang SJ; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts., Remland J; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Brais LK; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Bollenrucher N; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts., Chang E; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts., Ali LR; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Immunology, Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts., Lenehan PJ; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Immunology, Harvard Medical School, Boston, Massachusetts., Dolgalev I; Department of Medicine, NYU Langone Health, New York, New York.; Perlmutter Cancer Center, NYU Langone Health, New York, New York., Werba G; Perlmutter Cancer Center, NYU Langone Health, New York, New York.; Department of Surgery, NYU Langone Health, New York, New York., Lima C; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Keheler CE; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts., Sullivan KM; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts., Dougan M; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts., Hajdu C; Perlmutter Cancer Center, NYU Langone Health, New York, New York.; Department of Pathology, NYU Langone Health, New York, New York., Dajee M; Novartis Institute for Biomedical Research, Cambridge, Massachusetts., Pelletier MR; Novartis Institute for Biomedical Research, Cambridge, Massachusetts., Nazeer S; Novartis Pharmaceuticals, Cambridge, Massachusetts., Squires M; Novartis Pharmaceuticals, Cambridge, Massachusetts., Bar-Sagi D; Department of Medicine, NYU Langone Health, New York, New York.; Perlmutter Cancer Center, NYU Langone Health, New York, New York., Wolpin BM; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Nowak JA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Simeone DM; Perlmutter Cancer Center, NYU Langone Health, New York, New York.; Department of Surgery, NYU Langone Health, New York, New York., Dougan SK; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Immunology, Harvard Medical School, Boston, Massachusetts.
Publikováno v:
Cancer immunology research [Cancer Immunol Res] 2024 Sep 03; Vol. 12 (9), pp. 1221-1235.
Autor:
Till JE; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., McDaniel L; Personalis, Inc., Menlo Park, CA, USA., Chang C; Indiana University School of Medicine, Indianapolis, IN, USA., Long Q; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Pfeiffer SM; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Lyman JP; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Padrón LJ; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Maurer DM; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Yu JX; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Spencer CN; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Gherardini PF; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Da Silva DM; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., LaVallee TM; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Abbott C; Personalis, Inc., Menlo Park, CA, USA., Chen RO; Personalis, Inc., Menlo Park, CA, USA., Boyle SM; Personalis, Inc., Menlo Park, CA, USA., Bhagwat N; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Cannas S; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Sagreiya H; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Li W; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Yee SS; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Abdalla A; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Wang Z; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Yin M; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Ballinger D; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Wissel P; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Eads J; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Karasic T; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Schneider C; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., O'Dwyer P; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Teitelbaum U; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Reiss KA; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Rahma OE; Dana-Farber Cancer Institute, Boston, MA, USA., Fisher GA; Stanford University, Stanford, CA, USA., Ko AH; University of California, San Francisco, San Francisco, CA, USA., Wainberg ZA; University of California, Los Angeles, Los Angeles, CA, USA., Wolff RA; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., O'Reilly EM; Memorial Sloan Kettering Cancer Center, New York, NY, USA., O'Hara MH; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Cabanski CR; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Vonderheide RH; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Carpenter EL; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA. erical@upenn.edu.
Publikováno v:
Nature communications [Nat Commun] 2024 Jul 09; Vol. 15 (1), pp. 5763. Date of Electronic Publication: 2024 Jul 09.
Autor:
Ali LR; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Immunology, Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts., Lenehan PJ; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Immunology, Harvard Medical School, Boston, Massachusetts., Cardot-Ruffino V; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Immunology, Harvard Medical School, Boston, Massachusetts., Dias Costa A; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Katz MHG; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bauer TW; Department of Surgery, University of Virginia Health System, Charlottesville, Virginia., Nowak JA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Wolpin BM; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Abrams TA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Patel A; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Clancy TE; Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Wang J; Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Mancias JD; Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Reilley MJ; Division of Hematology and Oncology, Department of Medicine, University of Virginia Health System, Charlottesville, Virginia., Stucky CH; Mayo Clinic College of Medicine and Science, Mayo Clinic, Phoenix, Arizona., Bekaii-Saab TS; Mayo Clinic College of Medicine and Science, Mayo Clinic, Phoenix, Arizona., Elias R; Hartford Healthcare Cancer Institute, Hartford, Connecticut., Merchant N; Department of Surgery, University of Miami, Miami, Florida., Slingluff CL Jr; Department of Surgery, University of Virginia Health System, Charlottesville, Virginia., Rahma OE; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Dougan SK; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Immunology, Harvard Medical School, Boston, Massachusetts.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Feb 01; Vol. 30 (3), pp. 542-553.
Autor:
Reid P; Division of Rheumatology, Department of Medicine, University of Chicago Medical Center, Chicago, IL, USA., Sandigursky S; Division of Rheumatology, Department of Medicine, NYU Langone Health, New York, NY, USA., Song J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lopez-Olivo MA; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Safa H; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Cytryn S; Division of Internal Medicine, Department of Medicine, NYU Langone Health, New York, TX, USA., Efuni E; Division of Internal Medicine, Department of Medicine, NYU Langone Health, New York, TX, USA., Buni M; Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pavlick A; Medical Oncology, Weill Cornell Medical Center, New York, NY, USA., Krogsgaard M; Perlmutter Cancer Center, Department of Pathology, NYU Langone Health, New York, NY, USA., Abu-Shawer O; Department of Internal Medicine, Harvard Medical School, Boston, MA, USA.; Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA., Altan M; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Weber JS; Perlmutter Cancer Center, Department of Medicine, NYU Langone Health, New York, NY, USA., Rahma OE; Department of Internal Medicine, Harvard Medical School, Boston, MA, USA.; Department of Oncology, Dana Farber Cancer Institute, Boston, MA, USA.; Internal Medicine, Brigham and Women's Hospital, Boston, MA, USA., Suarez-Almazor ME; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Diab A; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Abdel-Wahab N; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Rheumatology and Rehabilitation, Faculty of Medicine, Assiut University Hospitals, Assiut, Egypt.
Publikováno v:
Oncoimmunology [Oncoimmunology] 2023 Oct 30; Vol. 12 (1), pp. 2261264. Date of Electronic Publication: 2023 Oct 30 (Print Publication: 2023).
Autor:
Hall WA; Froedtert and the Medical College of Wisconsin, Milwaukee, WI., Li J; The University of Pittsburgh, Pittsburgh, PA., You YN; University of Texas MD Anderson Cancer Center, Houston, TX., Gollub MJ; Memorial Sloan Kettering Cancer Center, New York, NY., Grajo JR; University of Florida, Gainesville, FL.; University of Florida Health Cancer Center, Gainesville, FL., Rosen M; Imaging and Radiation Oncology Core (IROC) Group, and the University of Pennsylvania, Philadelphia, PA., dePrisco G; Baylor Scott and White Health Baylor University Medical Center at Dallas, Dallas, TX., Yothers G; The University of Pittsburgh, Pittsburgh, PA., Dorth JA; University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH., Rahma OE; Dana-Farber/Harvard Cancer Institute, Boston, MA., Russell MM; Department of Surgery, David Geffen School of Medicine at UCLA, and VA Greater Los Angeles Healthcare System, Los Angeles, CA., Gross HM; Dayton Clinical Oncology Program, Dayton, OH., Jacobs SA; NSABP Foundation, Pittsburgh, PA., Faller BA; Missouri Baptist Medical Center/Heartland NCORP, St Louis, MO., George S; Stephenson Cancer Center University of Oklahoma Health Sciences Center, Oklahoma City, OK., Al Baghdadi T; Trinity Health Ann Arbor Hospital, Michigan Cancer Research Consortium (NCORP), Ann Arbor, MI., Haddock MG; Mayo Clinic, Rochester, MN., Valicenti R; University of California Davis Comprehensive Cancer Center/UC Davis School of Med/UC Davis Health, Sacramento, CA., Hong TS; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA., George TJ; University of Florida, Gainesville, FL.; University of Florida Health Cancer Center, Gainesville, FL.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Oct 10; Vol. 41 (29), pp. 4643-4651. Date of Electronic Publication: 2023 Jul 21.
Autor:
Hallisey M; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Dennis J; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Gabriel EP; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Masciarelli A; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Chen J; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Abrecht C; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Brainard M; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Marcotte WM; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Dong H; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts., Hathaway E; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Tarannum M; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts., Vergara JA; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts., Schork AN; Longwood Medical Area CyTOF Core, Dana-Farber Cancer Institute, Boston, Massachusetts., Tyan K; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts., Tarantino G; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Liu D; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Romee R; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts., Rahma OE; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts., Severgnini M; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Hodi FS; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Baginska J; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Electronic address: joanna_baginska@dfci.harvard.edu.
Publikováno v:
Laboratory investigation; a journal of technical methods and pathology [Lab Invest] 2023 Aug; Vol. 103 (8), pp. 100174. Date of Electronic Publication: 2023 May 09.
Autor:
Pappas L; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Baiev I; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA., Reyes S; Duke University School of Medicine, Durham, NC., Bocobo AG; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Jain A; Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Spencer K; Department of Medicine, NYU Langone Health Perlmutter Cancer Center, NYU School of Medicine, New York, NY., Le TM; Department of Medicine, University of Virginia Comprehensive Cancer Center, Charlottesville, VA., Rahma OE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Maurer J; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA., Stanton J; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA., Zhang K; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., De Armas AD; Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Deleon TT; Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ., Roth M; Department of Medical Oncology, St Luke's Cancer Institute, Kansas City, MO., Peters MLB; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA., Zhu AX; Jiahui International Cancer Center, Jiahui Health, Shanghai, China.; I-MAB Biopharma, Shanghai, China., Boyhen K; Yale University, New Haven, CT., VanCott C; Department of Medicine, HCA Florida South Tampa Hospital, Tampa, FL., Patel T; Department of Transplantation, Mayo Clinic, Jacksonville, FL., Roberts LR; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN., Lindsey S; The Cholangiocarcinoma Foundation, Herriman, UT., Horick N; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA., Lennerz JK; Center for Integrated Diagnostics, Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA., Iafrate AJ; Center for Integrated Diagnostics, Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA., Goff LW; Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, TN., Mody K; Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL., Borad MJ; Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ., Shroff RT; University of Arizona Cancer Center, University of Arizona, Tucson, AZ., Javle MM; Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Kelley RK; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Goyal L; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.; Department of Medicine, Division of Oncology, Stanford Cancer Center, Palo Alto, CA.
Publikováno v:
JCO precision oncology [JCO Precis Oncol] 2023 Aug; Vol. 7, pp. e2200594.